Author: healthprofessionalradio

Richard Marsden, CEO of Synairgen plc discusses full results from its SGO16 Phase II trial of its inhaled interferon beta formulation (SNG001) for the treatment of severe viral lung infections in COVID-19 patients.  The combined analysis of the home and hospital cohorts shows that breathless patients are more than 3 times as likely to recover on SNG001 than placebo. Unique to SNG001 is that it is inhaled therefore targeting response at the site of infection. 

Dr. Charlotte Owens, MD, Therapeutic Area Lead for Women’s Health in U.S. Medical Affairs at AbbVie discusses new data presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting on Real-World findings on elagolix in endometriosis and uterine fibroids.  Data highlights include positive treatment effects in endometriosis-associated pain, and higher physician satisfaction than other currently available treatments.

During the COVID-19 pandemic, healthcare research and training at all levels have been greatly impacted.  Paddy Mullen, CEO of BRANY (Biomedical Research Alliance of New York) and Bharat Krishna, MSc, MBA, Senior Vice President and Managing Director, CITI Program (Collaborative Institutional Training Initiative) discuss the results of a new survey of more than 7,000 respondents, including physicians, nurses, students, and researchers, that offer insights on where questions and concerns remain and what the future may hold as students and health care professionals attempt to return to normalcy at school and work. Visit CITI Program’s Youtube Channel.

Returning guest, Dr. Thomas Jones, Professor of Pediatrics and Adjunct Professor of Medicine at the University of Washington School of Medicine and Director of the Cardiac Catheterization Laboratories at Seattle Children’s Hospital and an investigator on the Medtronic Harmony™ Transcatheter Pulmonary Valve (TPV) pivotal trial discusses the one-year outcomes from the Pivotal Trial and 30-day outcomes from the Continued Access Study at a late-breaking session during SCAI (Society for Cardiovascular Angiography & Interventions) Scientific Sessions. The Harmony TPV is the first minimally invasive therapy created to treat patients with a specific type of congenital heart defect of the right ventricle.

Dr. Angelika Erwin, a board‐certified clinical geneticist and internist at Cleveland Clinic, as well as a porphyria expert and member of the Porphyrias Consortium discusses acute hepatic porphyria (AHP), when a doctor should suspect AHP in a patient and how to test for it.

Edmundo Gonzalez, CEO of Marpai Health discusses bringing AI and deep learning to the self-insurance market. What makes Marpai different is how they are leveraging data, stats, recent claims, and overall health to get ahead of potential health issues by analyzing data and providing predictions. For example if a patient is pre-diabetic, Marpai has TopCare, a group of experts in healthcare who are looking at the patient’s data and will recommend the top 10 experts to possibly see to address the health issue. 

Returning guest, Dr. Kendra Grubb, surgical director of the Structural Heart and Valve Center at Emory Healthcare in Atlanta discusses Medtronic’s announcement of early results from the OPTIMIZE PRO clinical study at the Society for Cardiovascular Angiography & Interventions (SCAI) 2021 Scientific Sessions.  The study evaluated procedure-related techniques and care pathways when using the self-expanding, supra-annular Evolut™ PRO and PRO+ TAVR systems in patients with symptomatic severe aortic stenosis.

37-year old Mical Roy discusses his stage II prostate cancer diagnosis in 2018 and his participation in the “Your Cancer Story” program which aims to help those living with cancer address the challenges at every stage of the journey via videos which Mical is featured in.  Now cancer free he has taken on the role of an advocate by mentoring, participating in local and national programs and bringing awareness to diversity in cancer care through research.

Dr. Andrew Makin, MD. Global Vice President of Medical Affairs at Oxford Immunotec, makers of The T-SPOT.COVID test discusses T-cell testing and how it can provide vital medical insights as we continue our journey through this pandemic.

Dr. Noam Emanuel, Co-Founder and CSO of PolyPid, a late-stage biopharma company aiming to improve surgical outcomes, discusses the second most prevalent type of Healthcare-Associated Infection (HAI), Surgical Site Infections (SSIs) which are responsible for 20 percent of all HAIs in US hospitals and often result in readmission and extended hospital stays. Current SSI prevention lies in IV antibiotic administration, but its systemic administration has limited efficacy and can result in resistance and toxicity. PolyPid is working to tackle this issue with its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology that pairs with medications, to enable precise delivery of drugs at effective release rates over durations ranging from several days to months.